NEW YORK, Oct. 20 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) today announced the appointment of William M. Appling as Senior Vice President of Medical Device Research and Development and Queensbury Facility Operations, and Daniel S. Johnston, PhD, to the position of Vice President of Pharmaceutical Research and Development. Mr. Appling and Dr. Johnston will be based in the Company's Queensbury, New York facility and report to Krishna Kandarpa, MD, PhD, Executive Vice President of Research and Development and Delcath's Chief Medical Officer.
"These key appointments now complete our Research & Development senior leadership team, and add significant expertise in medical device and pharmaceutical development to our organization as a whole," said Eamonn P. Hobbs, President and CEO. "Bill brings deep technical and organizational skills to our R&D and Operations teams, and Dan adds strong knowledge of oncology drug development that will be important as we pursue additional indications for our Chemosaturation System. We are pleased to welcome Bill and Dan to Delcath, and look forward to their contributions to successful commercialization of Chemosaturation."
Prior to joining Delcath, Mr. Appling was employed by AngioDynamics, Inc. where he held various management positions of increasing responsibility. Most recently, he served as Senior Vice President of Research and Development responsible for advanced research, process engineering, and managing an intellectual property portfolio of 285 issued patents and patent applications. Mr. Appling has been included as a named inventor on over 31 issued patents, and 30 pending patent applications. Prior to that, he was Manager of Product Development at E-Z-EM, Inc. Previously, Mr. Appling held product development positions at NAMIC, Inc., American Edwards Labs and Sheridan Catheter Corp.
Dr. Johnston was previously Principal Research Scientist in the Translational Medicine group at Pfizer, Inc. In this role, he identified and validated pharmocodynamic and patient selection biomarkers for preclinical and clinical assets and guided clinical development and asset differentiation. Dr. Johnston also served as Chair for the Oncology Early Biomarker Strategy Team at Pfizer. Prior to joining Pfizer, he was a Senior Research Scientist for Wyeth's Women's Health Research group, where he was a project team leader for three small molecule drug development projects. He earned his PhD at The Johns Hopkins University Bloomberg School of Public Health and completed his postdoctoral research at the School of Molecular Biosciences at Washington State University.
About Delcath Systems
Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug–delivery system for the treatment of other liver cancers and other organs, the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, actions by the FDA or other regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are made.
SOURCE Delcath Systems, Inc.